Fig. 1: Molecular evolution of independent prostate tumor nodules following neoadjuvant intense androgen deprivation therapy.

a–g Pre-treatment (a–c) or post-treatment (d–g) T2-weighted MRI (a–d), volumetric burden (b–e), and staining (c–g) of a large, semi-contiguous lesion sampled at multiple levels by mpMRI/TRUS fusion-guided biopsy (c) or whole-mount pathology (f, g) showing the location of biopsied and laser capture microdissected tumor foci. Arrowheads depict lesions on representative slices on MRI (a, d) or IDC-P (g). Arrows depict invasive carcinoma lesions. Scale bars: whole mount, 5 mm; biopsy, 1000 μm; insets, 100 μm. h Oncoprint depicting the alterations and histologic phenotypes of the microdissected tumor foci. i Phylogenetic tree depicting the relationships between baseline biopsy and prostatectomy tumor foci with respect to the alterations shown in the Oncoprint. Branches were constructed based on shared and unique mutations in each sample. j Venn diagram depicting the overlap between tumor foci based on somatic point mutations and large copy number alterations. Source data for the Venn diagram are provided in a source data file. B2/R2 = baseline/residual intraductal carcinoma, and B3/R3 = baseline/residual invasive carcinoma; B2 was intermingled with B3, and R2 was intermingled with R3.